Karsdal
Morten Karsdal, Kobenhavn K DK
Patent application number | Description | Published |
---|---|---|
20100220907 | Pathology indicating measure related to cartilage structure and automatic quantification thereof - A method for the analysis of three dimensional scan data representing an articular cartilage is provided to extract a quantitative parameter indicative of joint pathology. A measure representative of cartilage homogeneity is derived from this three dimensional image data. The measured value is compared with similar measured values previously established in respect of healthy joints and/or joints characterised by a pathology. | 09-02-2010 |
Morten Karsdal, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20090299769 | Prognostic osteoarthritis biomarkers - A computer based calculation of a prognostic index I of osteoarthritis based on biochemical and imaging based biomarkers a mathematical combination of said values, wherein a first imaging based biomarker is a measure of the quantity of a cartilage in a joint compartment, a second imaging based biomarker relating to the quality of said cartilage in said joint compartment, and wherein a value of said first biomarker indicative of a larger quantity of cartilage affects the index to make it predictive of more disease progression, and a value of said second biochemical marker indicative of a greater departure from the quality of disease free cartilage affects the index to make it predictive of more risk of disease progression, exemplified by | 12-03-2009 |
20100093014 | SCREENING FOR BONE ANABOLIC FACTORS - A method for screening for modulators of the secretion by an osteoclast of a wnt or a wnt signal enhancer comprises exposing osteoclasts in culture to a compound to be screened, exposing a wnt sensitive detection system to conditioned medium from said osteoclast culture, and determining whether a wnt signal is present in said medium by assaying for wnt mediated activation of bone formation by osteoblasts or by wnt mediated activation of LRP5 and or LPR6 signalling in a cell by detection of β catenin or detection of translocation of disheveled, axin, or Frat1 to the cell membrane of said cell. | 04-15-2010 |
20100323377 | BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT - A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, decorin, biglycan, collagen type III, CRP, ApoE, or elastin, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events. | 12-23-2010 |
Morten Karsdal, Kobenhavn O DK
Patent application number | Description | Published |
---|---|---|
20140295469 | In Vitro Assessment of Cardiovascular Events by Assay for Neo-Eptitopes of Titin Protein - A bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a titin protein by a proteinase comprises contacting a sample with an antibody specifically binding said neo-epitope and determining the level of binding. Partial sequences of titin that may be detected include: | 10-02-2014 |
20150064726 | Biochemical Markers for Neurodegenerative Conditions - A method of bioassay for the quantification of peptide fragments relevant to neurodegenerative conditions comprising a neo-epitope formed by cleavage of a Tau protein by a secretase such as ADAM10 comprises contacting a blood derived sample with an antibody specific for the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. Neo-epitope containing peptide levels are found to be inversely correlated to cognitive function. | 03-05-2015 |
20150118698 | Biochemical Markers for CVD Risk Assessment - A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events. | 04-30-2015 |
20150125964 | Detection of Diagnostic Peptides - An assay for citrullinated fragments of SOCS-2, Alpha 1 anti tyrpsin, versican, biglycan, laminin, or other protein having a terminal antibody binding site comprising citrulline in a blood derived sample shows diagnostic relevance in relation to rheumatoid arthritis or fibrotic disease. | 05-07-2015 |
20160061844 | PIIINP Neo-epitope Assay - Provided is a monoclonal antibody specifically reactive with a C-terminal neo-epitope of PIIINP comprised in a C-terminal amino acid sequence CPTGXQNYSP-COOH (SEQ ID NO: 4) in which X is Gly or Pro, and where the monoclonal antibody does not recognise or bind an elongated version of the C-terminal amino acid sequence CPTGXQNYSPQZ-COOH (SEQ ID NO: 5), in which Z is absent or is one or more amino acids of the sequence of collagen type III. Also provided is a method of immunoassay for detecting in a biological sample the C-terminal neo-epitope of PIIINP generated by N-protease cleavage of intact type III procollagen, by contacting the sample with the monoclonal antibody, and determining the amount of binding of the antibody. | 03-03-2016 |
20160077108 | Collagen Type VI Alpha-1 Assay - Provided is an antibody which binds to an epitope of collagen type VI alpha 1 comprised in the N-terminal globular domain internal amino acid sequence -ADWGQSRDAEEAISQ- (SEQ ID NO: 1). Also provided is a method of immunoassay for detecting in a biological sample an epitope comprised in the N-terminal globular domain internal amino acid sequence -ADWGQSRDAEEAISQ- (SEQ ID NO: 1) of collagen type VI alpha 1, by contacting the sample with the antibody, and determining the amount of binding of the antibody. | 03-17-2016 |
Morten A. Karsdal, Copenhagen O DK
Patent application number | Description | Published |
---|---|---|
20120045781 | PATHOLOGY BIOMARKER ASSAY - Methods of diagnosis or of quantitation of pathological conditions comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of pathology. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope. Neo-epitopes from, collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VI, elastin, biglycan, decorin, lumican, versican, C-reactive protein, ApoE and laminins are described. | 02-23-2012 |
Morten A. Karsdal, Kobenhavn DK
Patent application number | Description | Published |
---|---|---|
20130079295 | TREATMENT OF CARTILAGE RESORPTION - Excessive articular cartilage degradation is treated or prevented by administration to a mammal such as a human | 03-28-2013 |
Morten A. Karsdal, Kobenhavn O DK
Patent application number | Description | Published |
---|---|---|
20160091502 | TEXT NOT AVAILABLE - Methods of diagnosis or of quantitation of fibrosis are provided that comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of the measure in the patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a contacting protein fragments naturally present in the sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to the immunological binding partner to measure therein protein fragments comprising the neo-epitope. The protein is collagen type III, collagen type I, collagen type IV, collagen type V, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein. | 03-31-2016 |
Morten A. Karsdal, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20090204338 | Method of deriving a quantitative measure of the instability of calcific deposits of a blood vessel - A computer-implemented method of processing an image of at least part of a blood vessel to derive a measure indicative of the instability of calcific deposits in the blood vessel, said blood vessel containing at least one calcific deposit, comprises locating and annotating one or more calcific deposits. Using information derived from the annotation of said calcific deposits, the method further comprises calculating a measure reflecting either one or both of a) the aggregate of the deviations from roundness of individual calcific deposits, and b) up to at least a threshold value, the extent to which the separate calcific deposits are spaced from one another. | 08-13-2009 |
20100209940 | FIBROSIS BIOMARKER ASSAY - Methods of diagnosis or of quantitation of fibrosis comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a method comprising: | 08-19-2010 |
20110244482 | ASSESSMENT OF SUBCHONDRAL BONE REMODELLING BY MEASURING CATHEPSIN K FRAGMENTS OF COLLAGEN TYPE II - A method of assay to determine the extent of collagen type II resorption activity comprising measuring the level of fragments of collagen type II that contain a cathepsin K generated neo-epitope not shared by collagen type I by binding the neo-epitope with an antibody specific for the neo-epitope and detecting the level of binding of said binding partner. | 10-06-2011 |
20110244483 | ASSESSMENT OF PROTEIN DEGRADATION BY MEASUREMENT OF COLLAGEN FRAGMENTS - A method of assay measuring in a biological sample fragments of a protein that contain an N-terminal neo-epitope and a C-terminal neo-epitope, each generated by protease cleavage of said protein, comprises binding the N-terminal neo-epitope with a first specific antibody and binding the C-terminal neo-epitope with a second specific antibody, and detecting the extent of dual binding of said antibodies. | 10-06-2011 |
20110256639 | ASSESSMENT OF PROTEIN DEGRADATION BY MEASUREMENT OF ISOMERISED NEO-EPITOPE CONTAINING FRAGMENTS - A method of immunoassay for fragments of a protein such as type II collagen in a biological sample detects fragments having a first epitope containing an isomerised amino acid residue and a second epitope generated by cleavage of the protein by the use of respective antibodies binding each of the two epitopes. | 10-20-2011 |
20120046224 | TREATMENT OF DIABETES AND METABOLIC SYNDROME - Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating insulin resistance, and for reducing serum glucose levels. | 02-23-2012 |
Morten A. Karsdal, O Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20110142307 | VERTEBRAL FRACTURE PREDICTION - The risk of future fracture or deformity of vertebrae of a spine may be estimated by processing an image of at least one vertebra of a spine to compare data representing the appearance of the at least one vertebra with a statistical model of a corresponding part of a spine, the statistical model being formed from data representing images of spines for which information about the degree of fracture or deformity of each spine at a subsequent time is known, and deriving a measure of the similarity between the at least one vertebra of the spine and the model, which measure is representative of the likelihood that the spine will subsequently sustain a fracture or become deformed. | 06-16-2011 |
Morten Asser Karsdal, Kobenhavn DK
Patent application number | Description | Published |
---|---|---|
20130183385 | PEPTIDE ANALOGS FOR TREATING DISEASES AND DISORDERS - A peptide having a sequence selected from SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18. Said peptide used for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test. | 07-18-2013 |
20150196617 | Peptide Analogs for Treating Diseases and Disorders - Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. Treatment is effected with a combination therapy of metformin and a peptide with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 administered to a patient. | 07-16-2015 |